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Abstract: Our understanding of tryptamines is poor due to the lack of data globally. Tryptamines
currently are not part of typical toxicology testing regimens and their contribution to drug overdoses
may be underestimated. Although their prevalence was low, it is increasing. There are few published
data on the many new compounds, their mechanisms of action, onset and duration of action,
toxicity, signs and symptoms of intoxication and analytical methods to identify tryptamines and
their metabolites. We review the published literature and worldwide databases to describe the
newest tryptamines, their toxicology, chemical structures and reported overdose cases. Tryptamines
are 5-HT2A receptor agonists that produce altered perceptions of reality. Currently, the most
prevalent tryptamines are 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT), 5-methoxy-N,N-
diallyltryptamine (5-MeO-DALT) and dimethyltryptamine (DMT). From 2015 to 2020, 22 new analytical
methods were developed to identify/quantify tryptamines and metabolites in biological samples,
primarily by liquid chromatography tandem mass spectrometry. The morbidity accompanying
tryptamine intake is considerable and it is critical for clinicians and laboratorians to be informed of the
latest data on this public health threat.
Keywords: tryptamines; new psychoactive substances (NPS); analytical methods;
toxicology; psychedelics
1. Introduction
Psychedelics are a diverse group of naturally occurring and synthetic drugs that induce distorted
states of consciousness, perception, thinking and feeling [1]. Tryptamines share their core structure with
the neurotransmitter serotonin, also named 5-hydroxytryptamine (5-HT). The effects of psychedelics,
including those of tryptamines, are mediated by the 5-HT2A receptor [2–6] but may also be modulated
by interactions with other 5-HT receptors, monoamine transporters and trace amine-associated
receptors [6–14]. Furthermore, Luethi et al. presented a brief report based on correlations between
in vitro human 5-HT receptor affinities and their dose estimates [12], reporting that human doses for
psychedelics were significantly correlated with 5-HT2A and 5-HT2C receptor binding but not with
5-HT1A receptor binding. 5-HT2A receptors expressed on neocortical pyramidal cells are involved
in the psychedelic effects of tryptamines [3]. The activation of 5-HT2A receptors increases cortical
glutamate levels by a presynaptic receptor-mediated release from thalamic afferents. As serotonin
receptor agonists, psychedelics can produce synesthesia and altered perceptions of reality, where senses
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usually experienced separately are combined. The status of control for different psychedelics varies,
many are controlled under the Convention on Psychotropic Substances of 1971 (e.g., diethyltryptamine
(DET), dimethyltryptamine (DMT), α-ethyltryptamine (α-ET)), although some synthetic psychedelics
are not currently under international control.
Many countries report the use of psilocybin or magic mushrooms to the United Nations Office on
Drugs and Crime (UNODC) [1]. The ranking of drugs by Member States, based on prevalence data
from 123 countries, including 78 countries providing psychedelic data, suggests that the use of this
drug class is currently ranked on average 5.3 from 2013–2017, being less of a threat than the use of
cannabis, sedatives and tranquillizers, opioids and cocaine. From the available data on trends in the
use of different substances from 2001–2017, the majority of countries reported no significant change in
psychedelic use over time. Nonetheless, there are signs of an increase in the overall use of psychedelics
in recent years, particularly from 2012 to 2016, with the number of countries reporting increases
in the use of psychedelics greater than the number of countries reporting decreases. Furthermore,
according to the 2019 Global Drug Survey (GDS) [15], psychedelics were consumed by 40% of drug
users, with tryptamines the psychedelic class with the greatest increase in use. The psychedelics with
the greatest prevalence of use were lysergic acid diethylamide (LSD) (17.5%), psilocybin or magic
mushrooms (14.8%), DMT (4.2%), magic truffles (3.3%) and ayahuasca (1.1%) [16].
Several tryptamines occur naturally in a variety of plants, fungi and animals [1]. Some tryptamines
are also chemically synthesized, with several DMT analogs, such as alpha-methyltryptamine (α-MT)
and 5-methoxy-diisopropyltryptamine (5-MeO-DiPT), currently popular.
Several reviews report the toxicology of different NPS [17–21]; however, only two focused on
tryptamines [22,23]. In 2015, Tittarelli et al. [22] presented a summary of all the currently available
information on tryptamines and their derivatives, including pharmacology, chemical structures and
effects related to routes of administration and toxicities. Data were provided for twelve tryptamines
and/or derivatives and some intoxication reports. In the same year, Araújo et al. [23] provided an
overview for the same classic tryptamines plus other derivatives, providing additional detail on the
drugs’ toxicodynamics, preclinical physiological studies and adverse effects in humans. NPS and
tryptamines are constantly evolving, with new drugs appearing rapidly onto the market. The morbidity
associated with tryptamine intake is considerable and it is important for toxicologists to be informed of
the latest data on this public health threat. Our aim is to present the latest tryptamine intoxication cases
and new analytical methods to identify and quantify tryptamines in conventional and non-conventional
biological matrices over the last five years.
2. Results
Tryptamines are psychedelic drugs derived from decarboxylation of the amino acid tryptophan,
which produces the typical indole ring [24], giving these compounds the name “indolealkylamines.”
A compound’s chemical structure determines which receptors it can bind and activate, its absorption,
distribution, metabolism and elimination and its effects. In fact, minor additions and modifications to
the indolealkylamine backbone provide an endless supply of novel tryptamine structures, each with a
unique pharmacology. Table 1 presents the most common and newest tryptamines and metabolites,
with their common backbone structure and numerous ring substitutions. Tryptamines base structure is
represented on Figure 1.
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Table 1. Chemical structures of tryptamines.




Weight (g/mol) R1 R2 R3 R4 R5 R6 R7 R8
Tryptamine Tryptamine C10H12N2 160.2 H H H H H H H H
Ring unsubstituted tryptamines
α-MT α-methyltryptamine C11H14N2 174.2 H H CH3 H H H H H
α-ET α-ethyltryptamine C12H16N2 188.3 H H CH2CH3 H H H H H
DMT N,N-dimethyltryptamine C12H16N2 188.3 CH3 CH3 H H H H H H
DET N,N-diethyltryptamine C14H20N2 216.3 CH2CH3 CH2CH3 H H H H H H
MET N-methyl-N-ethyltryptamine C13H18N2 202.3 CH3 CH2CH3 H H H H H H
NMT N-methyltryptamine C11H14N2 174.2 H CH3 H H H H H H
DPT N,N-dipropyltryptamine C16H24N2 244.4 CH2CH2CH3 CH2CH2CH3 H H H H H H
DiPT N,N-diisopropyltryptamine C16H24N2 244.4 CH(CH3)2 CH(CH3)2 H H H H H H
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Table 1. Cont.




Weight (g/mol) R1 R2 R3 R4 R5 R6 R7 R8
4-Substituted tryptamines
Psilocin 4-Hydroxy-N,N-dimethyltryptamine C12H16N2O 204.3 CH3 CH3 H OH H H H H
Psilocybin 4-Phosphoryloxy-N,N-dimethyltryptamine C12H17N2O4P 284.3 CH3 CH3 H OPO3H2 H H H H
4-OH-MET 4-Hydroxy-N-methyl-N-ethyltryptamine C13H18N2O 218.3 CH3 CH2CH3 H OH H H H H
4-OH-DPT 4-Hydroxy-N,N-dipropyltryptamine C16H24N2O 260.4 CH2CH2CH3 CH2CH2CH3 H OH H H H H
4-OH-DET 4-Hydroxy-N,N-diethyltryptamine C14H20N2O 232.3 CH2CH3 CH2CH3 H OH H H H H
4-OH-MiPT 4-Hydroxy-N-methyl-N-isopropyltryptamine C14H20N2O 232.3 CH3 CH(CH3)2 H OH H H H H
4-OH-DiPT 4-Hydroxy-N,N-diisopropyltryptamine C16H24N2O 260.4 CH(CH3)2 CH(CH3)2 H OH H H H H
4-OH-DALT 4-Hydroxy-N,N-diallyltryptamine C16H20N2O 256.3 CH2CHCH2 CH2CHCH2 H OH H H H H
4-AcO-MET 4-Acetoxy-N-methyl-N-ethyltryptamine C15H20N2O2 260.3 CH3 CH2CH3 H OCOCH3 H H H H
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Table 1. Cont.




Weight (g/mol) R1 R2 R3 R4 R5 R6 R7 R8
4-Substituted tryptamines
4-AcO-DPT 4-Acetoxy-N,N-dipropyltryptamine C18H26N2O2 302.4 CH2CH2CH3 CH2CH2CH3 H OCOCH3 H H H H
4-AcO-DALT 4-Acetoxy-N,N-diallyltryptamine C18H22N2O2 298.4 CH2CHCH2 CH2CHCH2 H OCOCH3 H H H H
5-Substituted tryptamines
Bufotenine 5-Hydroxy-N,N-dimethyltryptamine C12H16N2O 204.3 CH3 CH3 H H OH H H H
5-OH-DiPT 5-Hydroxy-N,N-diisopropyltryptamine C16H24N2O 260.4 CH(CH3)2 CH(CH3)2 H H OH H H H
5-MeO-α-MT 5-Methoxy-alpha-methyltryptamine C12H16N2O 204.3 H H CH3 H OCH3 H H H
5-MeO-DMT 5-Methoxy-N,N-dimethyltryptamine C13H18N2O 218.3 CH3 CH3 H H OCH3 H H H
5-MeO-DPT 5-Methoxy-N,N-dipropyltryptamine C17H26N2O 274.4 CH2CH2CH3 CH2CH2CH3 H H OCH3 H H H
5-MeO-DiPT 5-Methoxy-N,N-diisopropyltryptamine C17H26N2O 274.4 CH(CH3)2 CH(CH3)2 H H OCH3 H H H
5-MeO-MiPT 5-Methoxy-N-methyl-N-isopropyltryptamine C15H22N2O 246.4 CH3 CH(CH3)2 H H OCH3 H H H
5-MeO-IPT 5-Methoxy-N-isopropyltryptamine C14H20N2O 232.3 H CH(CH3)2 H H OCH3 H H H
Int. J. Mol. Sci. 2020, 21, 9279 6 of 30
Table 1. Cont.




Weight (g/mol) R1 R2 R3 R4 R5 R6 R7 R8
5-Substituted tryptamines
5-MeO-MET 5-Methoxy-N-methyl-N-ethyltryptamine C14H20N2O 232.3 CH3 CH2CH3 H H OCH3 H H H
5-MeO-DET 5-Methoxy-N,N-diethyltryptamine C15H22N2O 246.4 CH2CH3 CH2CH3 H H OCH3 H H H
5-MeO-DALT 5-Methoxy-N,N- diallyltryptamine C17H22N2O 270.4 CH2CHCH2 CH2CHCH2 H H OCH3 H H H
5-Me-DALT 5-Methyl-N,N-diallyltryptamine C17H22N2 254.4 CH2CHCH2 CH2CHCH2 H H CH3 H H H
5-F-DALT 5-Fluoro-N,N-diallyltryptamine C16H19N2F 258.3 CH2CHCH2 CH2CHCH2 H H F H H H
5-Cl-DALT 5-Chloro-N,N-diallyltryptamine C16H19N2Cl 274.8 CH2CHCH2 CH2CHCH2 H H Cl H H H
5-Br-DALT 5-Bromo-N,N-diallyltryptamine C16H19N2Br 319.2 CH2CHCH2 CH2CHCH2 H H Br H H H
5-MeO-2-Me-DALT 5-Methoxy-2-methyl-N,N-diallyltryptamine C18H24N2O 284.4 CH2CHCH2 CH2CHCH2 H H OCH3 H H CH3
5-EtO-DALT 5-Ethoxy-N,N-diallyltryptamine C18H24N2O 284.4 CH2CHCH2 CH2CHCH2 H H OCH2CH3 H H H
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Table 1. Cont.




Weight (g/mol) R1 R2 R3 R4 R5 R6 R7 R8
Others
5,6-MD-DALT 5,6-Methylenedioxy-N,N-diallyltryptamine C17H20N2O2 284.4 CH2CH CH2CH H H OCH2O * H H
7-Et-DALT 7-Ethyl-N,N-diallyltryptamine C18H24N2 268.4 CH2CHCH2 CH2CHCH2 H H H H CH2CH3 H
7-Me-DALT 7-Methyl-N,N-diallyltryptamine C17H22N2 254.4 CH2CHCH2 CH2CHCH2 H H H H CH3 H
* Both R5 and R6 groups take part of the methylenedioxy ring.
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Figure 1. Tryptamines base structure.
Some tryptamine structures facilitate crossing the blood brain barrier, with a rapid onset of
highly potent effects and other structures prevent rapid metabolic degradation, increasing the duration
of effects [25]. Some tryptamines and derivatives are potent and short-acting psychedelics, whose
total duration of action is less than thirty min [25]. Such compounds must be taken parenterally or
enterally to experience the psychedelic effects. MAO is a mitochondrial flavin-dependent enzyme that
oxidatively deaminates serotonin and other biogenic and neuroactive amines and is present in the
liver, gut and brain of humans and other mammals. If tryptamines are orally ingested, protection
from peripheral degradation by a monoamine oxidase inhibitor (MAOI) may be necessary for activity.
Consequently, MAOI generally increases the pharmacological effects of such bioactive amines.
2.1. Tryptamines of Natural Origin
• Dimethyltryptamine (DMT)
DMT shares psychedelic and hallucinogenic activity with lysergic acid diethylamide (LSD) and
mescaline in terms of intensity and characteristics [22]. Common routes of DMT administration
are oral, insufflation, intravenous (IV) and smoking [24]. The time course of DMT administered
via inhalation of vaporized freebase or IV injection of a water-soluble salt is brief. The onset is
rapid, with full effects noted within 2 min of administration and subjective effects fully resolving
within 20–30 min [25]. Szára et al. also reported a rapid onset (2–5 min) of effects and a duration
of action of 30–60 min following intramuscular (IM) administration of 0.2–1 mg/kg DMT [26].
These authors reported that 0.7 mg/kg IM DMT resulted in diarrhea, nausea and vomiting. Additionally,
elevated heart rate, blood pressure and rectal temperature were reported by others following DMT
administration [27]. Psychologically, DMT can cause short-term emotional distress and in some
cases precipitate long-lasting psychosis. DMT is an agonist at the 5-HT1A, 5-HT2A and 5-HT2C
serotonin receptors and at the sigma-1 receptor. DMT’s broad agonist activity includes modulation
of physiological processes and regulation of inflammation through the sigma-1 and 5-HT receptors
and changing immune responses through the sigma-1 receptor. IM effects are usually less intense
than those following IV or inhalation. Oxidative deamination of DMT by monoamine oxidase (MAO)
produces indole-3-acetic acid (3-IAA) and 3-indole-aceturic acid [28]. Other metabolic pathways
include N-oxidation, N-demethylation and cyclization. DMT-N-oxide (DMT-NO), N-methyltryptamine
(NMT), 2-methyl-1,2,3,4-tetrahydro-beta-carboline (2-MTHβC) were also identified as minor DMT
metabolites [28].
DMT was first isolated from Mimosa hostiles, Mimosa tenuiflora and Mimosa root bark and is
also present in Psychotria viridis leaves and Virola plants, all parts of the beverage Ayahuasca [25].
Ayahuasca is produced by mixing different plants by native populations of the basin of the Amazon
river, suggested to be a drink with magic and curative powers. For the decoction preparation, the natives
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boil the bark or crushed stems of Banisteriopsis caapi together with other plants, including the leaves of
Psychotria viridis, a member of the Rubiaceae family. The two plants are distinguished by the content
of active compounds. Psychotria viridis contains DMT and Banisteriopsis caapi contains harmala
alkaloids (Peganum harmala or Syrian Rue) harmine, tetrahydroharmine and harmaline [29]. DMT is a
hallucinogen and the harmala alkaloids are MAO inhibitors that enhance DMT’s effects. Ayahuasca
is used to treat depression, anxiety and alcohol, tobacco [30] and drug addiction [31]. DMT is also
found as a minor alkaloid in the bark, pods and beans of Anadenanthera peregrina and Anadenanthera
colubrina [32].
In 2015, Paterson et al. [33] reported an acute intoxication in Los Angeles, California of an
unknown amount of smoked DMT by a 42-year-old male with no psychiatric history other than
multiple substance use disorders. He was on an involuntary legal hold for bizarre and disorganized
behavior that ultimately led to his hospitalization. During the interview in the emergency department
(ED), he reported smoking cannabis and three weeks before hospitalization, he began smoking DMT.
The subject was agitated, underweight and exhibited a marked disorientation to time. The patient
received supportive therapy, including sedation with benzodiazepines. After 21 days hospitalization,
he was discharged without complications. The urine toxicology analysis was performed 5 days after
ED admission and resulted positive only for benzodiazepines and negative for DMT.
In 2017, Bilhimer et al. [34] reported an acute intoxication involving DMT in the U.S. A 25-year-old
male with a history of mental illness had strong hallucinations and suicidal thoughts after injecting
DMT intravenously. The subject had dilated pupils, tachycardia (88 bpm) and systolic and diastolic
blood pressure of 116/71 mm Hg. His urine was immunoassay positive for amphetamines and DMT at
a concentration greater than 2000 ng/mL.
• Psilocybin and psilocin
Psilocybin (4-Phosphoryloxy-N,N-dimethyltryptamine) and psilocin (4-Hydroxy-N,N-
dimethyltryptamine or 4-OH-DMT), are contained in about 190 species of Psilocybe mushrooms but
the most well-known varieties are Psilocybe cubensis, Psilocybe semilanceata and Psilocybe Mexicana.
Psilocybin is a 4-substituted indoleamine that is dephosphorylated to psilocin, its pharmacologically
active metabolite [35]. Albert Hofmann [36] first isolated and identified psilocin from the Psilocybe
Mexicana mushroom in 1958. Psilocybe cubensis contains the highest concentrations of these two
tryptamines and is available frozen or as a dry powder or capsule [36]. In addition to its natural origin,
synthetic psilocin is available fresh or treated/preserved (dried or cooked). Psilocin is highly unstable
in solution and in the presence of oxygen and alkaline pH, it forms bluish and black degradation
products. This tryptamine is an isomer of bufotenine, differing only in the position of the hydroxyl
group [35]. Psilocin is orally active with a duration of action of 4–6 h [25]. Psilocin undergoes oxidative
deamination and forms the minor metabolite 4-hydroxyindole acetic acid (4-HIAA). This tryptamine is
also subject to phase II metabolism to the O-glucuronide, the main metabolite detected in human urine.
In recent years, fungis’ sclerotia, commonly called “magic truffles,” frequently supply the psychoactive
Psilocybe alkaloids, as Psilocybe sclerotia are not specifically included in the laws banning the sale,
the purchase and the use of such substances [37]. Terms for magic truffles include The Philosopher Stones,
Space truffles, Sclerotia Stones or Sclerotia. Psilocybin mushroom ingestion produces hallucinations as
early as 10 min post ingestion of 1–2 mg dried mushrooms and typically lasts from 4–12 h. Common
symptoms include dizziness, giddiness, nausea, weakness, muscle aches, shivering, anxiety, restlessness
and abdominal pain [38,39]. In 2018, Honyiglo et al. described the death of an 18 year old male in
France who jumped from the second floor and died following “hallucinogenic mushroom” intake [40].
The intoxication was confirmed by identification and quantification of psilocin in cardiac and femoral
blood (67 and 60 ng/mL respectively), urine (2230 ng/mL), bile (3102 ng/mL) and vitreous humor
(57 ng/mL). Gas chromatography time-of-flight detection with electron impact ionization (GC-EI-TOF)
was the analytical technique employed for identification and quantification.
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Currently, there is great interest in psilocybin in combination with psychotherapy to treat
psychiatric disorders like anxiety, depression and addiction to nicotine and drugs [41,42]. For example,
Grob et al. dispensed 0.2 mg/kg oral psilocybin, with a niacin placebo control to advanced-stage
cancer patients with anxiety [43]. There was a significant reduction in anxiety at 1 and 3 months
after treatment based on patients’ Speilberg State-Trait Anxiety Inventory (STAI). Carhart et al. [41]
administered psilocybin to treat 12 patients with moderate-to-severe, unipolar, treatment-resistant
major depression with two oral doses of psilocybin (10 mg and 25 mg, 7 days apart) in a supportive
setting. In addition, two randomized blinded controlled clinical trials demonstrated significant
long-term reductions in anxious depressed mood after psilocybin treatment [42,44]. Essential distress
also decreased and quality of life improved in terminally ill cancer patients after a single oral dose of
psilocybin. An open-label pilot study provided psilocybin in combination with cognitive behavioral
therapy to 15 treatment-resistant tobacco/nicotine-dependent smokers [45]. Smoking abstinence
was observed in 67% of patients at follow-up, documenting that psilocybin was more effective than
the most successful FDA-approved medication, varenicline [38]. Finally, a recent open-label pilot
study investigated psilocybin for the treatment of 10 alcohol-dependent individuals, with alcohol use
decreasing dramatically after the first psilocybin administration [46].
• 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT)
5-MeO-DMT is a natural tryptamine [25] that requires the presence of a MAOI to produce psychedelic
effects [22]. 5-MeO-DMT is ingested but unpublished reports describe inhalation as a common mean of
consumption with effects appearing within 60 sec and lasting 5–20 min [46]. Effects include auditory,
visual and time perception distortions, emotional experiences, memory impairment, asthma (12%),
high blood pressure (9%) and chronic fatigue syndrome (8%) [47]. There is also evidence that some
people use 5-MeO-DMT for treating psychiatric conditions, including depression, anxiety, post-traumatic
stress disorder and problematic substance use [47,48]. Tryptamine derivates like DMT, 5-OH-DMT and
5-MeO-DMT are metabolized by MAO-A that catalyzes an oxidative deamination forming IAA [49–51].
Brush et al. reported a poisoning related to 5-MeO-DMT and harmaline ingestion [22,52]. The victim
was a 17 year old male found collapsed after insufflation of 15–20 mg 5-MeO-DMT. GC/MS analysis of
urine only confirmed the presence of both harmaline and harmine. At ED admission, the patient had
hypertension and tachycardia (186 bpm) and was hyperthermic (40.7 ◦C). After administration of 2.5 mg
lorazepam, the symptoms began to resolve and the patient was discharged without complication.
Sklerov et al. described the death of a 25 year old white male found unresponsive in a national park
following ingestion of 5-MeO-DMT. Toxicological analyses revealed the presence of 5-MeO-DMT in
blood, urine, gastric contents, bile, kidney, brain and liver. Moreover, the heart blood sample contained
DMT (0.02 mg/L), 5-MeO-DMT (1.88 mg/L), tetrahydroharmine (0.38 mg/L), harmaline (0.07 mg/L)
and harmine (0.17 mg/L). The medical examiner pronounced the death as due to psychedelic amine
intoxication [22,53].
2.2. Tryptamines of Synthetic Origin
2.2.1. Ring Unsubstituted Tryptamines
• Alpha-methyltryptamine (α-MT)
α-MT is a psychedelic tryptamine sold as a white crystalline powder [54]. It was first developed
in 1960 as an antidepressant in the Soviet Union but its marketing was unsuccessful. α-MT’s
duration of effects is 8–14 h if ingested and 3–6 h when inhaled. α-MT effects are similar to those of
3,4-methylenedioxymethamphetamine (MDMA); both are empathogens and strong stimulants [54].
α-MT strongly inhibits re-uptake and release of monoamines dopamine, serotonin and norepinephrine
in mouse brain synaptosomes, also being a strong MAO inhibitor.
In September 2004, the U.S. Controlled Substances Act placed α-MT in Schedule I. α-MT is a
hallucinogen [54] and a stimulant with an alpha methyl group similar to amphetamine [55]. α-MT is
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generally available as a powder, tablet or capsule with oral doses of 5–10 mg producing stimulation,
20–30 mg hallucinogenic effects for up to 24 h, 60–80 mg considered a “strong” dose and up to
150 mg α-MT was previously self-administered. Generally, 5–20 mg free base is smoked. Snorting
or insufflation is an infrequent route of administration due to burning of the mucosa and a bad odor.
Inadequate solubility and lack of increased pharmacological effects limits IV administration [56].
The most frequent adverse effects described in the literature are anxiety, muscle tightness, vomiting,
hyperthermia, mild increase in blood pressure or respiratory rate, tachycardia, salivation, nausea,
impaired coordination, nervousness and restlessness [56,57].
Recently, Holstege et al. reported the intoxication and ED admission of a 21-year-old man following
α-MT ingestion [22,58]. He was hypertensive (BP 183/93 mmHg, heart rate 52 bpm), had a high fever,
felt disoriented, nervous and trembling. After medical treatment, the patient was discharged without
complication. No analytical confirmation was performed. In the same year, another α-MT intoxication
involved a 17-year-old male found naked and hallucinating [22,59]. In the ED, he was hyperthermic and
tachycardic (160 beats/min), presented with fever (37.3 ◦C), sweating and reactive 6–7 mm mydriatic
pupils. α-MT was identified in his urine by high-performance liquid chromatography coupled with
mass spectrometry (HPLC-MS). He was discharged with supportive therapy including benzodiazepines.
Boland et al., reported the first known α-MT death of a 22 year old male found unresponsive by his
roommate, who said he consumed 1 g α-MT 12 h prior. Iliac vein blood, gastric contents, liver and brain
were all α-MT positive at 2.0 mg/L, 9.6 mg/kg; 24.7 mg/kg and 7.8 mg/kg, respectively [22,60].
There are few α-MT pharmacokinetic data. Hydroxylation or oxidation of the indole ring at the 2-, 6-
and/or 7-positions was observed in male Wistar rats [61]. 2-oxo-α-MT, 6-hydroxy-α-MT, 7-hydroxy-α-MT
and 10-hydroxy-α-MT metabolites were identified in rat urine. Other rat α-MT metabolic pathways
include deamination to indole-3-acetone followed by oxidation to indole-3-carboxylic acid [61]. Also,
an isomer of α-MT, 5-(2-aminopropyl) indole (5-IT, 5API), appeared on the European drug market in
2011 [62].
• Alpha-ethyltryptamine (α-ET)
α-ET was first synthesized in 1947 as a potential synthetic precursor to the β-carbolines
but appeared on the clandestine market as an antidepressant (Monase) in the mid-1980s [63].
In 1986, Daldrup et al. described its first illicit use in Germany [64] and in 1993 the U.S. Drug
Enforcement Administration (DEA) included it on the Schedule I list [65]. α-ET may produce serotonin
neurotoxicity [66] but the exact mechanism is not understood. Serotonin neurotoxicity was produced by
the combined administration of a non-neurotoxic serotonin releasing agent and the dopamine releasing
agent S-amphetamine [67]. Other authors added that α-ET was the first tryptamine derivative, indeed,
the first non-phenylisopropylamine, shown to produce stimulus effects similar to those of MDMA on
unconditioned motor behavior in rats [62,68]. Like α-MT, other simple synthetic tryptamines, such as
α-ET, possess a methyl group on the alpha carbon, providing protection from MAO metabolism [56].
α-ET has a duration of action of 6–8 h when taken orally [23].
Morano et al. described a fatal intoxication involving α-ET ingestion [22,69]. The victim’s autopsy
revealed bilateral “pulmonary edema and generalized visceral congestion with some epicardial
petechiae.” α-ET intake was confirmed in blood (5.6 mg/L), urine (80.4 mg/L), vitreous (2.4 mg/L), bile
(22.0 mg/L), stomach contents (52.9 mg/g), liver (18.3 mg/g), kidney (24.0 mg/g) and brain (16.2 mg/g).
Daldrup et al. described another fatal case in which a psychotic man presented with agitation and
hyperpyrexia [22,64]. Blood toxicological analysis identified α-ET at 1.1 mg/L, with the cause of death
listed as malignant hyperthermia with α-ET contribution.
• Diethyltryptamine (DET)
DET is the ethyl analogue of DMT. It is orally active because the ethyl group prevents MAO degradation.
The active dose is 50–100 mg, with psychoactive effects lasting 2–4 h [70,71]. DET’s most common effects
include slight generalized tremors to gross athletic movements, visual distortion, hypersensitivity to light,
visual hallucinations, auditory perceptual distortions and olfactory hallucinations [72].
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• N-methyl-N-ethyltryptamine (MET)
MET is structurally related to DMT but little scientific information is available on its pharmacology
or toxicity in humans. Inhalation of 15 mg freebase MET or 80–100 mg oral freebase MET produce
effects [73]. Anecdotal reports describe the most common physical and psychological effects as physical
euphoria, tactile enhancement, increased heart rate and blood pressure, muscle cramps, teeth grinding,
pupil dilation, hallucinations and cognitive effects [73].
• N-methyltryptamine (NMT)
NMT is the product of methyl group additions to tryptamine by the enzyme indolethylamine-
N-methyltransferase [74]. In 2014, Gardner et al. demonstrated that NMT was a teratogen in pregnant
rats, producing fetal skeletal malformations and cleft palates [75]. MAO metabolism produces its
IAA metabolite.
• Dipropyltryptamine (DPT)
DPT is a synthetic tryptamine with a crystalline hydrochloride salt and an oily or crystalline
base, first reported in 1973 as a treatment for alcoholism [76]. DPT is a hallucinogen, also known
as “The Light.” DPT increases the intensity of music and color, with pleasant flashes of light and
sparkles, causing one to lose one’s ego and producing visual experiences [22]. DPT was an adjunct to
psychotherapy in the 1960s and 1970s but few peer-reviewed experimental studies were conducted [76].
Anecdotal internet reports describe it as a hallucinogen in humans following oral administration of
100–250 mg. Adverse physical and psychological “positive” effects include auditory hallucinations,
music enhancement, stimulation, euphoria and relaxation, as well as “negative” effects such as paranoia,
psychosis, anxiety, nausea, dizziness, increased heart rate and general tremor [77].
DPT strongly inhibited 5-HT reuptake into rat synaptosomes [12] and had moderate affinity and
partial agonism at the human 5-HT1A receptor [78]. In 2008, Fantegrossi et al. reported that DPT
elicited head-twitches in mice and rats suggesting that a primary site of action for DPT is the 5-HT2A
receptor [79]. Dailey et al. described a DPT intoxication case of a 19-year-old female [22,80]. The patient
arrived at the ED with tachycardia (200 bpm) and psychomotor agitation and was immediately sedated
with 3 mg lorazepam. No analytical confirmation was performed but a vial of DPT labelled “for
research purposed only” was found at the scene.
• Diisopropyltryptamine (DiPT)
DiPT is a synthetic hallucinogen, closely related structurally to DMT, a 5HT2A agonist and a
partial 5HT1A agonist that inhibits the serotonin transporter and vesicular monoamine transporter [81].
DiPT produces short-term visual and auditory hallucinations including hearing voices and bizarre
dream states at high doses and auditory distortion with deep tones at low doses [82].
2.2.2. 4-Substituted Tryptamines
• 4-Hydroxy-N-methyl-N-ethyltryptamine (4-OH-MET)
4-OH-MET is one of the most common synthetic tryptamines available online. 4-OH-MET,
synthesized by Shulgin et al. [82], has effects lasting 4–6 h. 4-OH-MET can produce a wide range
of effects including prickling, decreased ability to move and later anxiety, nervousness, paranoia,
tiredness and insomnia [31].
• 4-Hydroxy-N,N-dipropyltryptamine (4-OH-DPT)
4-OH-DPT is the 4-hydroxylated DPT derivative first synthesized by Shulgin et al. [82]. 4-OH-DPT
is a light beige or white powder [54] that acts as a 5-HT2A partial agonist. 4-OH-DPT also shares
structural similarity with psilocin [83]. Effects are dose dependent, with onset at 15–45 min and duration
of 5–8 h. According to user reports, synthetic 4-OH-DPT produces visual effects and hallucinatory
states [84].
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• 4-Acetoxy-N,N-dipropyltryptamine (4-AcO-DPT)
4-AcO-DPT is the 4-acetoxy derivative of DPT, is structurally similar to 4-AcO-DMT and
4-acetoxy-N, N- diisopropyltryptamine (4-AcO-DiPT) and is available as a white powder [54]. It is
available online and typically administrated orally or by insufflation. Its effects are dose dependent and
include hallucination, dissociation, confusion and flashbacks, as reported on Erowid by a 4-AcO-DPT
user [85].
• 4-Acetyloxy-N,N-diallyltryptamine (4-AcO-DALT)
4-AcO-DALT is a tryptamine derivative structurally linked to DALT and 5-MeO-DALT [54].
Users report taking 15–30 mg doses, with effects similar to those of hallucinogenic mushrooms or
4-AcO-DMT [85]. Effects lasted 1 h and were similar to those following mushroom intake, including
mental and visual effects and a slight cough and gagging [85].
• 4-Acetoxy-N-methyl-N-ethyltryptamine (4-AcO-MET)
4-AcO-MET, also known as matacetin, is a homolog of O-acetylpsilocin (4-AcO-DMT), an acetate
ester of 4-OH-MET and a homologue of 4-AcO-DMT. It is also a structural and functional psilocin
analogue and the 4-hydroxyl MET analogue [70].
Other synthetic 4-substituted tryptamines for which no scientific data are available are:
4-Hydroxy-diethyl-tryptamine (4-OH-DET), 4-OH-DiPT, 4-Hydroxy-N-methyl-N-isopropyltryptamine
(4-OH-MiPT), 4-Hydroxy-N-methyl-N-propyltryptamine or meprocin (4-OH-MPT), 4-Methoxy-N-
methyl-N-isopropyltryptamine (4-MeO-MiPT), 4-Methoxy-N,N-dimethyltryptamine (4-MeO-DMT),
4-Hydroxy-N,N-tetramethylenetryptamine (4-OH-pyr-T) and their acetic acid derivatives (e.g.,
4-Acetoxy-N,N-dimethyltryptamine (4-AcO-DMT), 4-Acetoxy-N,N-diethyltryptamine (4-AcO-DET)
and 4-Acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT).
2.2.3. 5-Substituted Tryptamines
• Bufotenine or 5-Hydroxy-N,N-dimethyltryptamine (5-OH-DMT)
5-OH-DMT is a serotonin derivative found in the skin secretions of some Brazilian Rhinella
toads [86], as well as in plants of the Leguminosae family and psychoactive mushrooms (Amanita
muscaria) [87]. When Bufo species are ingested, toxicity ensues, including hemiparesis, muscle jerking
and twitching, convulsions, altered mental status, slurred speech, headache, nausea, vomiting, severe
dyspnea and death [88–90]. Furthermore, effective dosage, route of administration and psychedelic
effects are widely known and reported in the literature [91,92]. It is metabolized by the enzyme
monoamine oxidase A (MAO-A) that catalyzes an oxidative deamination forming IAA [86].
• 5-Methoxy-α-methyltryptamine (5-MeO-α- MT)
At low dosages (15–30 mg orally, 5–20 mg smoked), 5-MeO-α-MT produces powerful
hallucinations [60]. Depending upon the individual, negative effects, including death, are more typical
at higher dosages (80–100 mg oral 5-MeO-α-MT) [6,59]. Neurologic manifestations that may occur
include agitation, restlessness, confusion and lethargy. Physical manifestations include vomiting, papillary
dilation, jaw clenching, tachycardia, mydriasis, salivation, diaphoresis and mild elevations in blood
pressure, temperature and respiratory rate may also occur [59].
• 5-Methoxy-N, N-dipropyltryptamine (5-MeO-DPT)
5-MeO-DPT is a 5-MeO-DMT structural isomer available as a white powder [54]. This molecule
is orally active, with dose-dependent effects. The most common reported effects included dizziness,
increased heart rate, tremor, anxiety and agitation.
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• 5-Methoxy-N, N-diisopropyltryptamine (5-MeO-DiPT)
“Foxy Methoxy” or 5-MeO-DiPT is a well-known psychedelic tryptamine in the illicit market [93].
The common routes of administration are oral, smoked and insufflations [94]. Noworyta-Sokołowska
et al. showed that 5-MeO-DIPT at doses of 5, 10 and 20 mg/kg induced head-twitch, hallucinations,
vomiting and tachycardia in rats [94]. Moreover, long-term exposure to 5-MeO-DIPT resulted in
development of post-hallucinogenic perception disorder. As described by Shulgin et al., users feel
the effects of 6–10 mg 5-MeO-DiPT 20 to 30 min after administration for 3–6 h [95]. 5-MeO-DIPT
is metabolized by five pathways, including hydroxylation, N-dealkylation [96] and reactions of
O-demethylation, with the N,N-diisopropyl groups converted to 5-hydroxy-N,N-diisopropyltryptamine
(5-OH-DiPT) that is further partly sulfated and glucuronidated [22,97].
The literature contains several reports of 5-MeO-DiPT intoxications. A 23-year-old male arrived
at the ED with paranoia and sensory distortion after ingesting 5-MeO-DiPT. 5-MeO-DiPT intake was
confirmed in blood and urine (0.14 and 1.6 µg/mL, respectively), suggesting consumption shortly before
intoxication [22,98]. Smolinske et al. investigated an intoxication case of a psychotic 19-year-old male
following ingestion of “Foxy,” transported to the ED and immediately treated with lorazepam [22,99].
Urine analysis was positive for phencyclidine and cocaine but was negative for 5-MeO-DiPT. In 2003,
Meatherall et al. described the intoxication of a 21-year-old man found in a state of confusion [22,100].
At ED admission, the patient was alert and oriented, with the only clinical observation his inability
to move his limbs. After 3.5 h, he was discharged from the hospital. Gas chromatography-mass
spectrometry (GC-MS) analysis of his urine revealed 1.7 µg/mL 5-MeO-DiPT, codeine, nicotine, cotinine,
acetaminophen and caffeine.
• 5-Methoxy-N,N-diallyltryptamine (5-MeO-DALT)
5-MeO-DALT was first synthesized by Shulgin et al. in 1980 [95] and was seized by police in
2006 as a “plant fertilizer” or “plant food” [29]. Active oral doses ranged from 12–20 mg [101], with
administration by the oral, nasal insufflation and IV routes. This drug produced dose-dependent effects
15 to 30 min after oral administration that lasted for 2 to 4 h. Adverse effects included vasoconstriction,
increased blood pressure, rapid heartbeat, headache, sweating, dilated pupils, bruxism, anxiety and
nausea. Meatherall et al. reported a fatal road crash following ingestion of 350 mg 5-MeO-DALT by a
26 year old male [22,100]. Toxicological findings included the presence of 5-MeO-DALT but there were
no data on drug quantification.
Michely et al. [102] identified 5-MeO-DALT phase I and II metabolites by liquid chromatography–
high-resolution mass spectrometry (LC–HRMS/MS). Metabolites were primarily derived from
hydroxylations, oxidations to oxo metabolites, N-dealkylations and O-demethylations.
• 5-Methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT)
5-MeO-MiPT or “moxy” was marketed as a “plant fertilizer.” Oral doses ranged from 1–3 mg (light),
3–8 mg (common) and 8–12 mg (strong), with typical 10–20 mg doses if inhaled [22,103]. The principal
effects lasted 3–7 h and included a general heightening of awareness, mild euphoria, psychedelic visual
effects, such as enhanced colors but also anxiety, nausea, confusion and paranoia. Repke et al. studied
if the effects of the drug would differ depending upon the route of administration [104]. If ingested
the effects were stimulating, with visual hallucinations prevailing. 5-MeO-MiPT metabolism studied
by LC-HRMS/MS identified six phase I metabolites following N-demethylation, O-demethylation,
demethylation and hydroxylation and N-oxide formation and hydroxylation of the parent compound
and N-O-bis-demethylation of the metabolite 5-OH-MiPT [105].
In 2019, Grafinger et al. reported that a 32 year old male went to the ED after the ingestion
of an “LSD-like substance” [106]. The cause of the intoxication was attributed to the combined use
of psychoactive substances. 5-MeO-MiPT was identified by LC-HR-MS/MS and quantified by liquid
chromatography coupled with mass spectrometry in tandem (LC-MS/MS) at 160 ng/mL in blood and
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3380 ng/mL in urine. The most abundant metabolites were identified as 5-methoxy-N-isopropyltryptamine
(5-MeO-NiPT), 5-hydroxy-N-methyl-N-isopropyltryptamine (5-OH-MiPT), 5-methoxy-N-methyl-N-
isopropyltrypt-amine-N-oxide (5-MeO-MiPT-N-oxide) and hydroxy-5-methoxy-N-methyl-N-isopropyl-
tryptamine (OH-5-MeO-MiPT).
Shimizu et al. reported an acute intoxication in a 27-year old male from 5-MeO-MiPT and
methylone use [107]. At the ED, he had psychomotor agitation, was sweating, had pyrexia (37.8 ◦C) and
tachycardia (150 bpm) and was hypertensive. The unknown powder that the man took was analyzed by
high-performance liquid chromatography (HPLC) and GC-MS to determine the intoxicating drug(s).
The powder contained 60% methylone (120 mg), a synthetic cathinone and 38% 5-MeO-MiPT (76 mg).
No analytical confirmation was performed and rapid drug screening tests did not show immunoreactivity
for other common drugs of abuse in urine and gastric fluid samples. He was discharged the day after
admission without complications.
• 5-Methoxy-N-methyl-N-ethyltryptamine (5-MeO-MET)
5-MeO-MET is a tryptamine structurally similar to 4-OH-MET and 4-AcO-MET [54]. This drug
is available in powder and crystal forms, with the common routes of administration ingestion and
insufflation. A drug-forum site reported a “threshold” dose of 1–4 mg, a “normal” dose 5–8 mg and a
“strong” dose 9–10 mg [108]. The onset of effects occurred at 1 min, with a limited duration of action
of only 40 min. The main adverse effects reported by users include euphoria, hallucinations, visual
alterations and anxiety.
• 5-Methoxy-N, N-diethyltryptamine (5-MeO-DET)
5-MeO-DET is an indolealkylamine structurally similar to DMT [105], with little data on its
behavioral effects. In 2011, Gatch et al. observed stimulant effects and increased locomotor activity
in rats [81]. After intraperitoneal and intraocular injection of 0.05 to 10 mg/kg 5-MEO-DET, effects
occurred within 30 min and lasted 80 to 90 min.
• 5-Methoxy-N,N-trimethyltryptamine (5-MeO-TMT)
5-MeO-TMT is a psychedelic tryptamine first synthesized by Shulgin et al. [82] that is smoked or
orally administered [104]. Toxicological information is still scarce but users suggest the oral dose is
75–150 mg but no duration of effects was reported. The effects include euphoria, visual distortions and
difficulty in sleeping.
2.3. Analytical Methods to Determine Tryptamines and/or Metabolites in Conventional and Non-Conventional
Biological Matrices
From 2010 to 2020, twenty-nine analytical methods were presented to determine tryptamines and
metabolites. Table 2 summarizes the analytical methods reported for the determination of tryptamines
in biological matrices, including information on sample size, sample preparation, instrumentation and
validation parameters.
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Table 2. Analytical methods to determine tryptamines in conventional and non-conventional biological matrices.
Analytes Sample(µL)
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Abbreviations: 5-MeO-DMT, 5-Methoxy-N,N-dimethyltryptamine; α-MT, α-methyltryptamine; DiPT, N,N-diisopropyltryptamine; DMT, N,N-dimethyltryptamine; DPT, N,N-
dipropyltryptamine; DET; N,N-diethyltryptamine; MiPT, N-methyl-N-isopropyltryptamine; 5-MeO-DALT, 5-Methoxy-N,N-diallyltryptamine; DPT, N,N-dipropyltryptamine; 4-OH-DET,
4-Hydroxy-N,N-diethyltryptamine; 4-OH-DIPT, 4-Hydroxy-N,N-diisopropyltryptamine; 4-AcO-DiPT, 4-Acetoxy-N,N-diisopropyltryptamine; 4-OH-MET, 4-Hydroxy-N-methyl-N-
ethyltryptamine; 4-OH-MIPT, 4-Hydroxy-N-methyl-N-isopropyltryptamine; 4-MeO-DMT, 4-Methoxy-N,N-dimethyltryptamine; 5-MeO-α-MT, 5-Methoxy-alfa-methyltryptamine;
5-MeO-DiPT, 5-Methoxy-N,N-diisopropyltryptamine; 5-MeO-DMT, 5-Methoxy-N,N-dimethyltryptamine; 5-MeO-MiPT, 5-Methoxy-N-methyl-N-isopropyltryptamine; MET, N-methyl-
N-ethyltryptamine; DET, N,N-diethyltryptamine; NMT, N-methyltryptamine; DALT, N,N-diallyltryptamine; 5-MeO-DALT, 5-Methoxy-N,N-diallyltryptamine; 2-Ph-DALT, 2-Phenyl-
N,N-diallyltryptamine; 4-AcO-DALT, 4-Acetoxy-N,N-diallyltryptamine; 4-OH-DALT, 4-Hydroxy-N,N-diallyltryptamine; 5-Me-DALT, 5-Methyl-N,N-diallyltryptamine; 5-MeO-2-
Me-DALT, 5-Methoxy-2-methyl-N,N-diallyltryptamine; 5-EtO-DALT, 5-Ethoxy-N,N-diallyltryptamine; 5-F-DALT, 5-Fluoro-N,N-diallyltryptamine; 5-F-2-Me-DALT, 5-Fluoro-2-methyl-
N,N-diallyltryptamine; 5-Cl-DALT, 5-Chloro-N,N-diallyltryptamine; 5-Br-DALT, 5-Bromo-N,N-diallyltryptamine; 6-F-DALT, 6-Fluoro-N,N-diallyltryptamine; 7-Me-DALT, 7-Methyl-N,N-
diallyltryptamine; 7-Et-DALT, 7-Ethyl-N,N-diallyltryptamine; 6-MD-DALT, 6-Methylenedioxy-N,N-diallyltryptamine; 5,6-MD-DALT, 5, 6-Methylenedioxy-N,N-diallyltryptamine;
5-MeO-IPT, 5-Methoxy-isopropyltryptamine; H, hair; B, blood; U, urine; S, serum; P, plasma; SPE, solid phase extraction; LLE, liquid liquid extraction; DLLME, dispersive liquid-liquid
microextraction; DBS, dried blood spots; UPLC, ultra-performance liquid chromatography; LC-MS/MS, liquid chromatography coupled with mass spectrometry in tandem; LC-
HRMS/MS, liquid chromatography high resolution coupled with mass spectrometry in tandem; DDA, data dependent acquisition; PDA, photodiode array acquisition; sMRM, scheduled
multiple reaction monitoring; dMRM, dynamic multiple reaction monitoring; QTrap, triple quadrupole linear ion trap mass spectrometer; UHPLC-HRMS, ultra-performance liquid
chromatography-high resolution mass spectrometry; GC-Orbitrap-MS, gas chromatography coupled with Orbitrap mass spectrometry; HPLC, high performance liquid chromatography;
UHPLC, ultra-high performance liquid chromatography; LC-QTOF, liquid chromatography coupled to a Quadrupole Time of Flight mass spectrometer; GC-MS, gas chromatography
coupled with mass spectrometry; ESI, electrospray ionization; HESI, heated electro spray ionization; EI, electron ionization; MRM, multiple reaction monitoring; GC-sIR, Gas chromatography
solid-state infrared analysis; AmAc, ammonium acetate; FA, formic acid; ACN, acetonitrile; AmFo, ammonium formate; MeOH, methanol; LOD, lower limit of detection; LOQ, limit of
quantification; NA, not available.
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Different biological matrices were employed for forensic purposes including conventional matrices
urine [102,112,114,118,121–123,125,126], blood [110,113–115,117–119,121,123], plasma [109,111,112,118]
serum [112] and unconventional matrices oral fluid [120] and hair [116,124]. Protein precipitation
is a simple sample preparation method, providing sufficient extraction efficiency while simplifying
extraction and preparation time. Different protein precipitation methods [115,117,119,121] include
different solvents for blood extraction but methanol is the most common solvent. Different sample
preparation techniques include protein precipitation [113,116,117,119] for urine, serum and blood
samples, acid hydrolysis [102,121,122] for urine, centrifugation [102,111,112,114–117,119,121–124,126]
for blood, plasma and urine samples, washing [109,114,116,125] for plasma, blood and hair samples,
enzymatic hydrolysis for urine samples [112], solid phase extraction (SPE) [109–111,114], liquid-liquid
extraction (LLE) [114,120], dispersive liquid-liquid microextraction (DLLME) [115] and a solvent
extraction for dried blood spots (DBS) [113]. Tryptamine is a relatively labile analyte but it remains
stable in an acidic environment. Some analytical methods described the use of acidic solvents to extract
drugs from blood.
Most analytical methods included chromatographic separations and mass spectrometry
detection. LC-MS/MS [109,111–117,119,123,124], LC-HRMS/MS [102,122], GC-MS [102,118,122,123],
LC-MS [118,123] and ultra-performance liquid chromatography-high resolution mass spectrometry
(UHPLC-HRMS/MS) [121] analytical methods are most common for forensic toxicology purposes.
Different approaches utilized triple quadrupole full-scan mode [102,126], triple quadrupole multiple
reaction monitoring (MRM) [109–111,113,116,119,124] with data dependent acquisition (DDA) [102] and
photodiode array acquisition PDA [118], single quadrupole time of flight (TOF) [121,125]. Even with
powerful analytical instrumentation, these substances’ identification can be missed for many reasons
including the fact that the reference mass spectrum may not be available in libraries for full-scan
mode and fragments generated in single ion monitoring (SIM) mode show nondescript fragmentation
patterns [22].
Low limits of detection (LOD) are key for identifying tryptamines; two analytical methods achieved
LODs of 0.10–0.15 ng/mL for 5-MeO-DiPT, with the same sample volume and LC-MS/MS technology
but different sample preparation techniques [117,119]. Michely et al. had LODs of 10–50 ng/mL
for DALT and 5-MeO-DALT by GC-MS, with a 2.5 mL urine sample [102] but later achieved LODs
of 1–5 ng/mL using LC-HRMS/MS and fifty times lower sample volume [122]. Also, Martin et al.
determined psilocin in 500 µL plasma with a 0.1 ng/mL LOD [111], whereas in their more recent
method they present an LOD of 0.05 ng/mL using 1 mL of the same matrix with a different sample
preparation [112]. Fagiola et al. detected DMT in blood with a 2.5 ng/mL LOD [123], while Adamowicz
et al. identified DMT with a 0.88 ng/mL LOD in a smaller blood volume but a longer sample preparation
procedure [117], both with LC-MS/MS. For 5-MeO-DMT, Fagiola et al. [123] had a similar LOD as
Adamowicz et al. (2.50 and 2.61 ng/mL, respectively) but the first author employed a higher sample
volume [117]. More rigorous sample preparation can reduce background noise and improve detectability.
Adamowicz et al. accomplished a lower 4-MeO-DiPT LOD compared to that of Vaiano et al. [119] with
the same sample volume and mass spectrometer.
Yan et al. [126] analyzed urine for 5-MeO-DiPT and metabolites using a GC-Orbitrap-MS method
characterized by LODs of 1 ng/mL and a concentration range of 1–2.8 ng/mL in five authentic urine samples.
In this study the authors also identified two metabolites, 5-OH-DiPT and 5-MeO-DiPT but without
presenting their LODs [126]. LODs from 0.06–2.98 ng/mL blood were described for 16 tryptamines
but sensitivities for some metabolites were not included in the method of Adamowicz et al. [117].
Michely et al. [102] achieved the same LOD for 5-MeO-DALT as Ambach et al. [114], with 100 µL
urine without an extraction technique, while the latter group required 250 µL urine but had a more
comprehensive LLE sample cleanup. Ambach et al. also developed an analytical method for tryptamines
in 10 µL dried blood spots (DBS), reaching LODs of 1–2.5 ng/mL for 5-MeO-DALT, 5-MeO-DMT, AMT,
DiPT, DMT and DPT [113]. In the Brandt et al. method for 15 tryptamines, the LODs were not provided,
despite their being used to propose a metabolic pathway for tryptamines [118]. Generally, the most
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commonly detected compounds were 5-MeO-DiPT, 5-MeO-DALT and DMT, perhaps because their
metabolic pathways are already well known and toxicologists know how to identify the drugs.
3. Discussion
The effects of tryptamine administration are determined by their structures, as each compound
has a different spectrum of receptor affinities and related psychoactive phenomena. In addition,
the dose of tryptamine derivatives and duration of their effects commonly differ among compounds
and depend on their potency and route of administration [127]. Given the complexity, variety and
variability of the effects of psychedelics in humans, it is difficult to define animal behavior models to
study psychedelic activity.
Currently, there are few data on metabolic pathways or specific enzymes involved in tryptamines
biotransformation. Data suggest that not all tryptamines have a common metabolic pathway, that pathways
vary based upon the nature and position of substituents in the molecule. Here we include the most
current available information on tryptamines and on the reported tryptamine fatalities and intoxications.
More than twenty new tryptamines were introduced to the market since the most recent reviews five years
ago [22,23] and we include their data here. In addition, all the new analytical methods for tryptamines
and reports of their detection in biological matrices are described. These data are valuable for physicians,
toxicologists, pathologists, ED staff and others.
Despite tryptamines’ increasing consumption [1,15] recent or current use of psychedelics in
general is quite low in most countries and there is limited scientific literature on their epidemiology
and patterns of intake. From 2010–2020, there were few intoxication cases and even fewer fatalities
due to tryptamines consumption in North America and the EU. It is unknown if there are few cases or
if their detection is missed. Deaths caused by tryptamines’ consumption certainly could be missed but
if they are abused alone, it is more likely that health authorities will continue the search to identify
the toxicant. It is important to mention that in most cases the cause of death is not due to the toxicity
of the drug but to its psychedelic effects that can lead to harmful and potentially fatal behaviors.
From the fifteen case reports presented, only four resulted in a fatality [53,60,69,100]. Furthermore,
three case reports [58,80,107] had no analytical confirmation, making it uncertain what drug was
taken and whether the observed effects were due to the suspected drug. Tryptamines are frequently
taken in combination with other drugs of abuse, for instance DMT and cannabis [33]; DMT and
amphetamines [34]; 5-MeO-DiPT, cocaine and phencyclidine or codeine [100] and 5-MeO-MiPT and
methylone [107], with effects resulting from the individual drugs and the interactions between drugs,
based on their mechanisms of action.
The lack of knowledge of the constantly changing tryptamine availability on the internet may
be driven by the lack of tryptamine testing availability. Currently, no common immunoassay-based
screening test exists for tryptamine derivatives and tryptamines are not usually included in routine
toxicological analyses. Therefore, wide-ranging laboratory analysis are needed for the identification of
these drugs, employing techniques that can reach the required high sensitivity to avoid false negative
toxicological findings and selectivity to avoid false positive tryptamine results.
Antemortem and postmortem tryptamines toxicological data most likely underestimates their
prevalence because most laboratories do not routinely test for this class of drugs. Unfortunately,
this results in a lack of knowledge of the drugs’ pharmacology and toxicology, clinical effects and
drug-drug interactions following co-ingestions [1]. There also are few data on tryptamine and metabolite
concentrations to guide toxicologists’ interpretation of tryptamine biological sample results. Currently,
the use of psychedelics and anesthetic or dissociative substances remains quite low compared to other
psychoactive substances but it is increasing [15].
4. Materials and Methods
A literature search was performed on PubMed from January 2010 to March 2020. Keywords
included the names of the individual tryptamine compounds identified in laboratory casework and
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the published literature, general terms such as novel psychoactive substances, analytical methods,
toxicology, chromatography, quantification, gas chromatography (GC), liquid chromatography (LC),
psychoactive effects, pharmacology, pharmacodynamics, pharmacokinetics and drug classes including
tryptamines, natural origin, synthetic origin, which were cross referenced with outcome-based terms
such as overdose, intoxication, death, hospitalization, fatalities and case reports. The selection
of relevant articles included the following criteria: articles acknowledging tryptamines or toxicity
including studies focusing on the pharmacodynamics, analytical methods in conventional (i.e., blood,
serum/plasma and urine) and alternative matrices (i.e., oral fluid and hair) and case reports published
in English. Further research manuscripts were retrieved through the reference lists of selected articles
and from reports and websites of international drug agencies, including the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) [128], the UNODC [129] and the World Health
Organization (WHO) [130].
Three of the co-authors screened all articles independently to determine their relevance to the
present review and were included if at least two co-authors selected the article. The following topics
(based on title and abstract review) served to categorize each article: tryptamines pharmacology
(pharmacodynamics and pharmacokinetics), chemistry, detection and identification, fatalities and
intoxications. Sixty-four original research papers, thirty-one review articles and fifteen case reports
were included in the review.
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